Estudo Laboratorial do Uso da Cefovecina em Cães Sadios

Abstract

Cefovecin is the newest semisynthetic cephalosporin. The drug is indicated for treatment of skin and urinary infections. The aim of this study was to evaluate the influence of cefovecin therapy on the hemogram, platelet distribution width (PDW) and platelet count, blood gas, serum proteins, and on the activity of urea and creatinine. Ten healthy dogs (males n=4; females n=6), average weight of 10.03±3.54 kg were used. The animals were kept in individual cages all over the experiment. The dogs were nourished with a commercial feed ad libitum drinking. The animals were submitted to the clinical and laboratory examinations as an inclusion criterion for the experiment. Sodium cefovecin (Convenia®) was subcutaneously administered (8mg/kg) to the dogs. Clinical evaluation and laboratorial analysis was performed prior and at 1, 2, 3, 7, 14 and 21 days post treatment (dpt). Despite to be in accordance with the reference values, a statistically significant (p<0.05) decrease in total serum protein, globulin, hemoglobin and packed cell volume was observed at the 21 dpt. The platelet distribution width (PDW) and platelet count were increased at seven and 21 days (p>0.05), respectively. No changes in urea and creatinine activities, blood gas and leukocyte values were observed in the dogs after the administration of cefovecin. In conclusion, cefovecin can be administered in healthy dogs without causing significant laboratory abnormalities